Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Perampanel Oral Suspension in Pediatric Epilepsy (1 Month to <4 Years)
NCT02914314Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2017
- Primary completion
- Aug 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of perampanel in epilepsy, sponsored by Eisai Co., Ltd. Primary endpoints: Dose Normalized Area Under the Concentration-Time Curve for Dosing Interval at Steady State, Dose Normalized Maximum (Peak) Steady-state Concentration and 2 more. Started Feb 2017; status: completed.
02
Drugs
perampanel
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02914314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914314.